{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:51:17Z","timestamp":1791165077396,"version":"4.1.0"},"reference-count":131,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T00:00:00Z","timestamp":1318464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation. \u00a9 2011 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.23953","type":"journal-article","created":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T19:58:41Z","timestamp":1318535921000},"page":"31-41","source":"Crossref","is-referenced-by-count":79,"title":["Pharmacologic approaches to the treatment of Huntington's disease"],"prefix":"10.1002","volume":"27","author":[{"given":"Charles S.","family":"Venuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Kieburtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,13]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161206777698693"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.2.141"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1986.tb04506.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0022-3565(25)25665-8","article-title":"Biochemical and pharmacological studies of RO 1\u20139569 (tetrabenazine), a nonindole tranquilizing agent with reserpine\u2010like effects","volume":"127","author":"Quinn GP","year":"1959","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410120308"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1242\/jeb.196.1.251"},{"key":"e_1_2_7_8_2","volume-title":"Xenazine (tetrabenazine) package insert","year":"2009"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.67.4.550"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90563-6"},{"issue":"3","key":"e_1_2_7_11_2","first-page":"118","article-title":"Psychosedative effects of tetrabenazine (RO 1\u20109569) on hyperactive and disturbed mentally retarded patients","volume":"21","author":"Lende N","year":"1960","journal-title":"Dis Nerv Syst"},{"key":"e_1_2_7_12_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1192\/bjp.108.453.225","article-title":"A trial of tetrabenazine (\u201cNitoman\u201d) in disturbed mentally subnormal patients","volume":"108","author":"Kanjilal GC","year":"1962","journal-title":"J Ment Sci"},{"key":"e_1_2_7_13_2","first-page":"207","article-title":"Treatment of Huntington's chorea with tetrabenazine (Nitoman)","volume":"125","author":"Moller\u2010Christensen B","year":"1963","journal-title":"Ugeskr Laeger"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21161"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-62"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21222"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3180ca77ea"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199808000-00006"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M582"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.10.1450"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.1.84"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.47.8.848"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1159\/000114879"},{"key":"e_1_2_7_25_2","first-page":"282","article-title":"Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements","volume":"4","author":"Gimenez\u2010Roldan S","year":"1989","journal-title":"Neurologia"},{"key":"e_1_2_7_26_2","first-page":"177","article-title":"Fluphenazine decanoate in the treatment of chorea: a double\u2010blind study","volume":"20","author":"Terrence CF","year":"1976","journal-title":"Curr Ther Res Clin Exp"},{"key":"e_1_2_7_27_2","first-page":"1","article-title":"Effect of oral fluphenazine on Huntington's chorea","volume":"4","author":"Whittier JR","year":"1968","journal-title":"Int J Neuropsychiatry"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01573339"},{"key":"e_1_2_7_29_2","first-page":"573","article-title":"Huntington's disease: clinical effects of a short\u2010term treatment with pimozide","volume":"24","author":"Arena R","year":"1980","journal-title":"Adv Biochem Psychopharmacol"},{"key":"e_1_2_7_30_2","first-page":"307","article-title":"Therapeutic experiences in the treatment of hyperkineses with the neuroleptic pimozide (Antalon, Orap) in the frame of Huntington chorea","volume":"34","author":"Siegmund R","year":"1982","journal-title":"Psychiatr Neurol Med Psychol (Leipz)"},{"key":"e_1_2_7_31_2","first-page":"114","article-title":"Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study","volume":"83","author":"McArthur AW","year":"1976","journal-title":"N Z Med J"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(82)90628-8"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998409109601"},{"key":"e_1_2_7_34_2","first-page":"725","article-title":"[Clinical trial of tiapride in patients with dyskinesia (author's transl)]","volume":"58","author":"Chouza C","year":"1982","journal-title":"Sem Hop"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.47.8.844"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/026988119601000213"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/026988119400800411"},{"key":"e_1_2_7_38_2","unstructured":"Assistance Publique\u2010Hopitaux de Paris. Neuroleptic and Huntington Disease Comparison of: olanzapine la tetrabenazine and tiapride (NEUROHD). In: ClinicalTrials.gov. Bethesda MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00632645. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00632645?erm= tiapride&rank=1. Accessed August 19 2011."},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200209000-00007"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103174009"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23402"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.136.3.317"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.5.821"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.63.1.35"},{"key":"e_1_2_7_45_2","first-page":"69","article-title":"Short\u2010term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri F","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2002.01197.x"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C297"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22376"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08040503"},{"key":"e_1_2_7_50_2","first-page":"1","article-title":"Aripiprazole in the treatment of Huntington's disease: a case series","volume":"5","author":"Ciammola A","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.22.3.352-c.e4"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199704000-00023"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199902000-00020"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0741-1"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181ebb285"},{"key":"e_1_2_7_56_2","unstructured":"NeuroSearch. NeuroSearch A\/S \u2010 Company Announcement. NeuroSearch A\/S announces the results of additional assessment and analysis of data from the Phase III MermaiHD study with Huntexil\u00ae in Huntington's disease. 2010 News Releases. Published: 2010\u201004\u201028 09:43:26 CEST. Available at:https:\/\/newsclient. omxgroup.com\/cdsPublic\/viewDisclosure.action?disclosureId=3989 90&messageId=480255. Accessed August 19 2011."},{"key":"e_1_2_7_57_2","unstructured":"McGarryA KieburtzK RembrattA TedroffJ Huntington Study Group HART Investigators.A randomized double\u2010blind placebo\u2010controlled trial of ACR16 in Huntington's Disease. Poster session presented at: Huntington Study Group Meeting 4th Annual Huntington Disease Clinical Research Symposium; October 16 2010 La Jolla CA. Rochester NY: Huntington Study Group."},{"key":"e_1_2_7_58_2","unstructured":"KieburtzK.Open\u2010label extension study of pridopidine (ACR16) in the symptomatic treatment of Huntington disease (OPEN\u2010HART). In: ClinicalTrials.gov. Bethesda MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT01306929. Available at:http:\/\/clini caltrials.gov\/ct2\/show\/NCT01306929?term=pridopidine&rank=1. Accessed August 19 2011."},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1.153"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000096019.71649.2B"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21181"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199204000-00009"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.5.694"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000068165.07883.64"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.7.996"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.63.3.597"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.08.005"},{"key":"e_1_2_7_68_2","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.1.1.101"},{"key":"e_1_2_7_69_2","unstructured":"Corey\u2010BloomJ.Study of memantine to treat Huntington's disease. In: ClinicalTrials.gov. Bethesda MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00652457. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00652457?term= memantine+huntington%27s&rank=1. Accessed August 19 2011."},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200201210-00011"},{"key":"e_1_2_7_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200201210-00029"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.1177\/147323000803600505"},{"key":"e_1_2_7_73_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000169025.09670.6d"},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.12.1582"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddl252"},{"key":"e_1_2_7_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00862983"},{"key":"e_1_2_7_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(76)90295-2"},{"key":"e_1_2_7_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.04.058"},{"key":"e_1_2_7_79_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2002.00447_4.x"},{"key":"e_1_2_7_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20235"},{"key":"e_1_2_7_81_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000240945.44370.f0"},{"key":"e_1_2_7_82_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.9.1133"},{"key":"e_1_2_7_83_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T"},{"key":"e_1_2_7_84_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000238106.10423.00"},{"key":"e_1_2_7_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03654.x"},{"key":"e_1_2_7_86_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:BEBM.0000017097.75818.14"},{"key":"e_1_2_7_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02434871"},{"key":"e_1_2_7_88_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.164491"},{"key":"e_1_2_7_89_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-100174"},{"key":"e_1_2_7_90_2","unstructured":"BernalesSW ProtterSA HungDT.Dimebon includes neurite outgrowth and mitochondrial stabilization. In: Proceedings of the Society for Neuroscience Annual Meeting November 15\u201319 2008; Washington DC. Washington DC: Society of Neuroscience;2008."},{"key":"e_1_2_7_91_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.334"},{"key":"e_1_2_7_92_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674379804300909"},{"key":"e_1_2_7_93_2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2007.9.2\/arosenblatt"},{"key":"e_1_2_7_94_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120319"},{"key":"e_1_2_7_95_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181b2ac0a"},{"key":"e_1_2_7_96_2","unstructured":"BeglingerLJ FiedorowiczJG BiglanK CavinessJ JorgeR.CIT\u2010HD: study in Huntington's disease. In: ClinicalTrials.gov. Bethesda MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00271596. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00271596. Accessed August 19 2011."},{"key":"e_1_2_7_97_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283348018"},{"key":"e_1_2_7_98_2","volume-title":"Rilutek (riluzole) package insert","year":"2009"},{"key":"e_1_2_7_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00192-9"},{"key":"e_1_2_7_100_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1997.6520"},{"key":"e_1_2_7_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)12137-S"},{"key":"e_1_2_7_102_2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1096\/fj.02-0143fje","article-title":"Riluzole enhances expression of brain\u2010derived neurotrophic factor with consequent proliferation of granule precursor cells in rat hippocampus","volume":"16","author":"Katoh\u2010Semba R","year":"2002","journal-title":"FASEB J"},{"key":"e_1_2_7_103_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.30501"},{"key":"e_1_2_7_104_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0615-y"},{"key":"e_1_2_7_105_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1103-3"},{"key":"e_1_2_7_106_2","first-page":"597","article-title":"Coenzyme Q10 effects in neurodegenerative disease","volume":"5","author":"Spindler M","year":"2009","journal-title":"Neuropsychiatri Dis Treat"},{"key":"e_1_2_7_107_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410206"},{"key":"e_1_2_7_108_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.397"},{"key":"e_1_2_7_109_2","unstructured":"CudkowiczM McDermottM KieburtzK.Coenzyme Q10 in Huntington's Disease (HD). In: ClinicalTrials.gov. Bethesda MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00608881. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT 00608881?term=Coenzyme+Q10++huntington&rank=1. Accessed August 19 2011."},{"key":"e_1_2_7_110_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000"},{"key":"e_1_2_7_111_2","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2001.0406"},{"key":"e_1_2_7_112_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000070186.97463.A7"},{"key":"e_1_2_7_113_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000160388.96242.77"},{"key":"e_1_2_7_114_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000194318.74946.b6"},{"key":"e_1_2_7_115_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000090629.40891.4B"},{"key":"e_1_2_7_116_2","unstructured":"HerschSM SchifittoG RosasD.Creatine safety tolerability and efficacy in Huntington's disease (CREST\u2010E). In: ClinicalTrials.gov. Bethesda MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00712426. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00712426?term=creatine+huntington&rank=1. Accessed August 19 2011."},{"key":"e_1_2_7_117_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501507102"},{"key":"e_1_2_7_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.05.006"},{"key":"e_1_2_7_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2005.06.021"},{"key":"e_1_2_7_120_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.50"},{"key":"e_1_2_7_121_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.180"},{"key":"e_1_2_7_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03310-9"},{"key":"e_1_2_7_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70381-7"},{"key":"e_1_2_7_124_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.5.687"},{"key":"e_1_2_7_125_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904239106"},{"key":"e_1_2_7_126_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1997.6685"},{"key":"e_1_2_7_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0963-6897(97)00028-6"},{"key":"e_1_2_7_128_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110205"},{"key":"e_1_2_7_129_2","unstructured":"Assistance Publique\u2010Hopitaux de Paris. MIG\u2010HD: Multicentric Intracerebral Grafting in Huntington's Disease. In: ClinicalTrials.gov. Bethesda MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00190450. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00190450. Accessed August 19 2011."},{"key":"e_1_2_7_130_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e328304b692"},{"key":"e_1_2_7_131_2","first-page":"CD006455","article-title":"Therapeutic interventions for disease progression in Huntington's disease","volume":"8","author":"Mestre T","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_132_2","doi-asserted-by":"publisher","DOI":"10.3727\/000000007783464687"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23953","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.23953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:40:14Z","timestamp":1760967614000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.23953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":131,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/mds.23953"],"URL":"https:\/\/doi.org\/10.1002\/mds.23953","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,13]]}}}